A child in Europe has become the second person globally to receive the commercial gene therapy Strimvelis, marking a milestone in the development of gene-based treatments. The therapy, designed to cure a rare inherited immune disorder, was administered nearly a year after receiving regulatory approval for sale in Europe.

First Patient Under New Regimen
GlaxoSmithKline reported that the treatment was given in March, though details about the patient's nationality and payment arrangements remain undisclosed. The delay between approval and treatment was attributed to the complexities of cross-border reimbursement within Europe. Currently, the treatment is available at a single medical facility in Milan, Italy.
Context and Significance
Strimvelis offers a definitive cure for severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID), a condition leaving infants without a functional immune system. The therapy involves extracting a patient’s bone marrow cells, editing them outside the body using a viral vector to insert a correct ADA gene, and reinfusing these cells into the patient.
Only one other patient has previously received gene therapy for an inherited disease outside clinical trials, using Glybera in 2015. Glybera was criticized for its high cost and low demand, leading to its withdrawal from the European market by its developer.
Industry Challenges and Market Outlook
The prospects for Strimvelis are closely watched as several gene therapies are nearing approval and market entry. In the U.S., a nearby company is preparing to seek approval for a gene therapy targeting blindness, highlighting a burgeoning pipeline.
Despite the promise, gene therapies face hurdles, including their complex manufacturing processes and high prices. Strimvelis is priced at approximately 594,000 euros ($648,000), making it one of the most expensive medications worldwide. This pricing underscores ongoing debates over accessibility and cost justification for rare disease treatments.
The market's trajectory remains uncertain, as delays in establishing reimbursement mean wider availability could still be years away. Experts have voiced concern over the lengthy process required to integrate these therapies into standard healthcare systems.
Access and Treatment Specifics
The therapy specifically targets ADA-SCID, affecting roughly 15 children annually across Europe. The treatment is categorized as ex vivo gene therapy, requiring specialized conditions for administration. It has been confined to the San Raffaele Hospital in Milan due to the need for a controlled environment.
While the European Union's cross-border healthcare framework is expected to facilitate access across member states, some patients are opting for experimental treatments through clinical trials at other institutions, such as Great Ormond Street Hospital in London and the University of California, Los Angeles.
Future Directions
GlaxoSmithKline is exploring methods to expand access by developing cryogenic storage options, which would allow cells to be transported more easily across Europe. The company anticipates treating multiple patients throughout the year as these logistical hurdles are addressed.
This event signals both a breakthrough and a test case for the commercial viability of gene therapies aimed at rare diseases. As the industry grapples with pricing and reimbursement challenges, the coming months will be critical in determining whether this treatment path can become more widely accessible.
Corrections and clarifications: contact@avorz.com
How this was reported: /how-we-report/